Literature DB >> 1568732

Effect of cyclosporine on colchicine secretion by a liver canalicular transporter studied in vivo.

K V Speeg1, A L Maldonado, J Liaci, D Muirhead.   

Abstract

The multidrug resistance transport protein is a normal constituent of the liver canalicular membrane, although its function has not been defined in vivo. Colchicine, a multidrug resistance substrate, is eliminated mainly by the liver. Cyclosporine reverses multidrug resistance in vitro, presumably by inhibiting the multidrug resistance transporter. This study assesses biliary colchicine elimination and the effect of cyclosporine on this process. After cyclosporine administration biliary colchicine clearance decreased from 11.6 +/- 0.8 to 2.2 +/- 0.4 ml/min.kg (p less than 0.05), and the colchicine bile/plasma ratio decreased from 166 +/- 9 to 38 +/- 5 (p less than 0.05). Cremophor EL (a cyclosporine vehicle) transiently inhibited biliary colchicine clearance and colchicine bile/plasma ratio, but to a much smaller extent than cyclosporine in vehicle. Biliary cyclosporine clearance was 0.122 and 0.024 ml/min.kg after bolus doses of 2 or 10 mg/kg intravenously, respectively. Cyclosporine bile/plasma ratio was 1.3 to 5.2. When cyclosporine was given 16 hr before colchicine infusion, biliary colchicine clearance decreased 39% (p less than 0.05), and colchicine bile/plasma ratio decreased 51% (p less than 0.05). Thus colchicine is actively secreted into bile and will be useful in the study of the multidrug transporter in vivo. Cyclosporine profoundly inhibits colchicine secretion into bile but is itself mainly metabolized rather than secreted. If competition for a common carrier is the basis for the interaction, then cyclosporine represents a drug that binds to but is not transported by the canalicular transporter.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1568732     DOI: 10.1002/hep.1840150524

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  13 in total

Review 1.  Gout in solid organ transplantation: a challenging clinical problem.

Authors:  Lisa Stamp; Martin Searle; John O'Donnell; Peter Chapman
Journal:  Drugs       Date:  2005       Impact factor: 9.546

2.  Effect of steady-state atorvastatin on the pharmacokinetics of a single dose of colchicine in healthy adults under fasted conditions.

Authors:  Matthew W Davis; Suman Wason
Journal:  Clin Drug Investig       Date:  2014-04       Impact factor: 2.859

3.  Microdialysis assessment of microfibrous collagen containing a P-glycoprotein-mediated transport inhibitor, cyclosporine A, for local delivery of etoposide.

Authors:  H Sato; H Kitazawa; I Adachi; I Horikoshi
Journal:  Pharm Res       Date:  1996-10       Impact factor: 4.200

Review 4.  Multidrug resistance (MDR) genes in haematological malignancies.

Authors:  K Nooter; P Sonneveld
Journal:  Cytotechnology       Date:  1993       Impact factor: 2.058

5.  Role of S-adenosylmethionine on the hepatobiliary homeostasis of glutathione during cyclosporine A treatment.

Authors:  A I Galán; M E Muñoz; J Palomero; C Moreno; R Jiménez
Journal:  J Physiol Biochem       Date:  2000-09       Impact factor: 4.158

Review 6.  Multidrug resistance in cancer chemotherapy.

Authors:  N H Patel; M L Rothenberg
Journal:  Invest New Drugs       Date:  1994       Impact factor: 3.850

Review 7.  Effects of drug transporters on volume of distribution.

Authors:  Anita Grover; Leslie Z Benet
Journal:  AAPS J       Date:  2009-04-28       Impact factor: 4.009

8.  P-glycoprotein is more efficient at limiting uptake than inducing efflux of colchicine and vinblastine in HL-60 cells.

Authors:  X Declèves; O Chappey; B Boval; E Niel; J M Scherrmann
Journal:  Pharm Res       Date:  1998-05       Impact factor: 4.200

9.  Effect of cyclosporine on colchicine partitioning in the rat liver.

Authors:  K V Speeg; A L Maldonado
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

Review 10.  Colchicine: its mechanism of action and efficacy in crystal-induced inflammation.

Authors:  George Nuki
Journal:  Curr Rheumatol Rep       Date:  2008-07       Impact factor: 4.592

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.